Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» NMOSD
NMOSD
AstraZeneca’s rare disease unit overcomes FDA snub to expand Ultomiris in NMOSD
Fierce Pharma
Mon, 03/25/24 - 10:31 pm
AstraZeneca
Soliris
NMOSD
Ultomiris
FDA blocks new use for AstraZeneca's Ultomiris
Pharmaphorum
Wed, 09/6/23 - 10:10 am
AstraZeneca
Ultomiris
Soliris
FDA
NMOSD
New data shows Roche's Enspryng significantly reduces neuromyelitis optica spectrum disorder relapses
PM Live
Sat, 10/16/21 - 11:25 pm
Roche
Enspryng
NMOSD
Chugai’s Enspryng receives regulatory approval from FDA for neuromyelitis optica spectrum disorder
Pharmaceutical Business Review
Mon, 08/17/20 - 10:31 am
Chugai
FDA
Enspryng
NMOSD
AstraZeneca spinoff scores maiden FDA approval, where it will field Alexion competition and an imminent Roche rival
Endpoints
Fri, 06/12/20 - 10:40 am
Viela Bio
AstraZeneca
Uplinza
FDA
NMOSD
Genentech posts long-term data on near-approval Soliris rival
Fierce Biotech
Fri, 05/22/20 - 10:46 am
Genentech
satralizumab
Soliris
Alexion
NMOSD
Roche trumpets data for Soliris rival in NMOSD after US, EU filings
Pharmaforum
Mon, 12/2/19 - 10:34 am
Roche
satralizumab
neuromyelitis optica spectrum disorder
NMOSD
Led by BioNTech, six biotechs line up for October IPOs
Endpoints
Sat, 09/28/19 - 04:38 pm
IPOs
MRNA
melanoma
inebilizumab
NMOSD
blood cancer
solid tumors
BioNTech
ADC Therapeutics
Viela Bio
Frequency Therapeutics
Aprea Therapeutics
Monopar Therapeutics
Viela Bio Files for $150 Million IPO
CP Wire
Fri, 08/30/19 - 10:05 am
Veila Bio
IPOs
inebilizumab
NMOSD
Viela Bio Files for $150 Million IPO
Fri, 08/30/19 - 09:52 am
Viela Bio
inebilizumab
NMOSD
Alexion's cash cow Soliris just got fatter as FDA greenlights another blockbuster indication
Endpoints
Fri, 06/28/19 - 12:36 pm
Alexion
Soliris
FDA
autoimmune disease
NMOSD
Viela reports detailed Phase II/III data for rare CNS disorder therapy
BioCentury
Tue, 05/7/19 - 06:55 pm
Viela
inebilizumab
NMOSD
AstraZeneca Spinoff Viela Bio Reports Positive Phase IIb Trial in Rare Disease
BioSpace
Thu, 01/3/19 - 04:13 pm
Viela Bio
AstraZenecal
N-MOmentum
inebilizumab
NMOSD
Alexion’s Soliris wows in rare disease PhIII trial, opening up a new franchise worth $500M-$700M
Endpoints
Mon, 09/24/18 - 03:33 pm
Alexion
Soliris
clinical trials
NMOSD